{"filings":[{"id":2079477,"accession_number":"0001299130-26-000117","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2026-08-05T20:23:30+00:00","items":["2.02","2.05","5.02","7.01","9.01"],"status":"ready","headline":"PacBio Q2 revenue $39M, net loss $44.7M; CEO Henry steps down, Van Oene appointed; restructuring cuts 8% workforce","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $39.0M (down 2% YoY); GAAP net loss $44.7M ($0.14 loss per share); non-GAAP net loss $41.9M.","Revio placements 20, Vega placements 26; consumable revenue $20.1M; annualized Revio pull-through ~$202K.","Full-year 2026 revenue guidance $155-165M; commenced SPRQ-Nx chemistry rollout at $345/genome.","CEO Christian Henry steps down effective Aug 5; COO Mark Van Oene appointed President and CEO; Henry stays as advisor through Dec 2026.","Restructuring plan cuts ~40 employees (8% workforce); expects $30-40M annualized OpEx reduction by end 2027; $2M pre-tax charges in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-08-05","daily_digest_url":"/daily/2026-08-05","daily_digest_rank":9},{"id":1554397,"accession_number":"0001299130-26-000111","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2026-07-09T20:32:58+00:00","items":["5.02"],"status":"ready","headline":"Director Christopher M. Smith resigns from Pacific Biosciences board effective July 8, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher M. Smith resigned from the Board effective July 8, 2026.","No disagreement between Mr. Smith and the Company on operations, policies, or practices.","No replacement director has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":863436,"accession_number":"0001299130-26-000092","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2026-06-04T21:19:08+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve 16M share increase in equity plan at Pacific Biosciences annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2020 Equity Incentive Plan, adding 16,000,000 shares for future grants.","Four Class III directors elected: Ericson, Ordoñez, Smith, Gibson, Henry, Milligan.","Ernst & Young ratified as independent registered public accounting firm for FY2026.","Advisory say-on-pay proposal approved with 114,050,930 votes for, 21,239,989 against.","Annual meeting had ~65% of shares represented (203,009,375 of 310,487,099 outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91991,"accession_number":"0001299130-26-000076","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PacBio Q1 rev flat at $37.2M; consumable record but instrument miss; FY26 guidance $165-175M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $37.2M flat YoY; consumable record $21.8M (+8% YoY), instrument revenue $9.7M (-12% YoY) below expectations.","GAAP net loss $8.3M ($0.03/sh) vs $426.1M loss ($1.44/sh) in Q1 2025 (incl. restructuring); non-GAAP loss $35.9M ($0.12/sh).","Full year 2026 revenue guidance $165M-$175M; cash $276M after $48.1M net from short-read asset sale.","SPRQ-Nx beta to broad Revio launch in May; Basecamp Research project for ~100K samples selected PacBio.","EMEA revenue +17% YoY; non-GAAP gross margin 37% vs 40% on component costs and promotions."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":37178000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102449,"accession_number":"0001299130-26-000053","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"PACB settles patent lawsuit with PGI, will pay $23M to $25M; CAO resigns","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Michele Farmer resigns as CAO effective March 21, 2026; no severance or disagreement.","CFO Jim Gibson assumes principal accounting officer role; no compensation change.","Binding term sheet with Personal Genomics of Taiwan (PGI) resolves all patent claims and counterclaims.","PACB receives worldwide non-exclusive license to US Patent 7,767,441 and 5.5-year covenant not to sue.","Payments: $8M in Q1 2026, then $5M each Q1 of 2027-2029; 2027 payment may rise up to $2M if revenue thresholds met."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102448,"accession_number":"0001299130-26-000046","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PacBio appoints Chris Gibson (Recursion co-founder) to board; effective March 3, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to 10; Gibson appointed Class I director with term expiring at 2026 annual meeting.","Gibson also named to PacBio's Science and Technology Committee.","He is co-founder and Chairman of Recursion (RXRX), an AI-driven biotech with a drug discovery platform.","No related party transactions between Gibson and PacBio; standard indemnification agreement to be entered.","Company cites Gibson's experience in AI, automation, and high-dimensional biology as strategic for HiFi sequencing data tools."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102447,"accession_number":"0001299130-26-000017","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PacBio Q4 revenue $44.6M, consumable record; GAAP net loss $40.4M, non-GAAP loss narrows","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $44.6M (+14% YoY); consumable revenue record $21.6M (+15% YoY).","GAAP net loss $40.4M ($0.13/share) vs GAAP net income $2.4M in Q4 2024 (incl $154.4M debt restructuring gain).","Non-GAAP net loss $37.6M ($0.12/share) vs $55.3M ($0.20) in Q4 2024; non-GAAP gross margin 40% vs 31%.","Vega placements 42 in Q4 (140 FY); Revio placements 21 Q4 (61 FY). Annualized Revio pull-through ~$242,000.","Completed sale of short-read assets for ~$48.1M net cash; cash & investments $279.5M at year end."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":160005000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102446,"accession_number":"0001299130-26-000012","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pacific Biosciences CEO and COO swap interim responsibilities effective Jan 28, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Christian Henry assumes interim oversight of operations and R&D from COO Mark Van Oene.","COO Mark Van Oene assumes interim oversight of sales and customer support from CEO Christian Henry.","No changes to titles or compensation for either executive as a result of the reassignment.","Effective date of role adjustment: January 28, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102445,"accession_number":"0001104659-26-009014","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"PacBio completes sale of short-read sequencing assets to Illumina for $48.1M net cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold certain short-read DNA sequencing IP and related technologies to Illumina for $50M gross; net cash proceeds $48.1M.","Illumina assumed certain liabilities and granted PacBio a non-exclusive license back to certain IP.","Transaction closed Jan 30, 2026; company to focus on long-read sequencing and accelerate SPRQ-Nx chemistry launch.","Proceeds strengthen balance sheet; $1.9M paid to former Apton equity holders to waive milestone obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102444,"accession_number":"0001299130-26-000005","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"PacBio Q4 revenue $44.6M (+14% YoY); full year $160M (+4%); record consumables","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue ~$44.6M vs $39.2M YoY; full year ~$160M vs $154M.","Instrument revenue Q4 ~$17.3M (Q4'24 $15.3M); consumables ~$21.6M (Q4'24 $18.8M) a record.","Vega placements 42 in Q4 vs 7 a year ago; Revio placements 21 vs 23.","Ending cash $279.5M vs $389.9M; management cites reduced cash burn and SPRQ-Nx catalyst.","PacBio presents at J.P. Morgan Healthcare Conference on Jan 12, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":160005000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118719,"accession_number":"0001299130-25-000165","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PacBio Q3 revenue $38.4M, net loss narrows to $38M; consumables hit record $21.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $38.0M ($0.13 loss per share) vs $60.7M ($0.22) YoY; non-GAAP net loss $36.8M ($0.12).","Consumable revenue record $21.3M (+15% YoY); instrument revenue $11.3M (down 33% YoY).","Non-GAAP gross margin improved to 42% from 33% YoY; operating expenses cut to $53.9M from $62.4M.","Revio systems shipped 13 (vs 22); Vega systems shipped 32; cash and investments $298.7M.","Launched SPRQ-Nx chemistry to reduce sequencing costs up to 40%; Sequel II CNDx approved in China."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":115360000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135223,"accession_number":"0001299130-25-000152","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PacBio Q2 revenue up 10.5% YoY to $39.8M; GAAP net loss narrows to $41.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss per share of $0.14 improved from $0.64 YoY; non-GAAP EPS -$0.13 vs -$0.20.","Consumable revenue $18.9M (+11% YoY); service & other revenue $6.7M (+56% YoY).","Shipped 15 Revio and 38 Vega systems; Revio annualized pull-through ~$219K/system.","Cash, equivalents, and investments $314.7M, down from $509.8M a year earlier.","Non-GAAP operating expenses cut to $58.1M from $71.0M YoY; CEO cites disciplined cost management."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":76919000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152201,"accession_number":"0001299130-25-000140","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve 23M share increase to 2020 Equity Plan; Annual meeting results","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved 23M share increase to 2020 Equity Plan: 85.4M for, 43.6M against, 56.4M broker non-votes.","Annual meeting on June 4, 2025: 186.1M shares voted of 300.0M outstanding (62% representation).","Class III directors elected: William Ericson, Kathy Ordoñez, and Christopher M. Smith.","Ernst & Young ratified as independent auditor for FY 2025 (162.2M for, 22.6M against).","Non-binding advisory vote on NEO compensation approved (78.4M for, 50.5M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152200,"accession_number":"0001299130-25-000099","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PacBio Q1 GAAP net loss $426M on restructuring; consumable revenue record, non-GAAP loss narrows","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $37.2M, down 4% YoY; consumable revenue record $20.1M (+26% YoY).","GAAP net loss $426.1M ($1.44 EPS) includes $381.8M restructuring charges; non-GAAP net loss $44.4M ($0.15).","Restructuring plan targets $45-50M annualized non-GAAP opex reduction by end of 2025; focuses on long-read business.","Shipped 28 Vega and 12 Revio systems (Revio down from 28 YoY); non-GAAP gross margin improved to 40% from 33%.","Independent investigation of employee allegations may delay Q1 10-Q filing; company sees no material financial impact."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":37153000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152199,"accession_number":"0001299130-25-000083","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"PacBio reports preliminary Q1 revenue $36.9M, down 5% YoY; cuts annual opex run rate by $45-50M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 2025 revenue $36.9M vs $38.8M YoY; instrument revenue fell to $10.8M from $19.0M.","Record consumable revenue of $20.1M (up from $16.0M); shipped 28 Vega systems in Q1 (vs 0 prior).","Announces plan to reduce annualized non-GAAP opex run rate by $45-50M; expects ~$5M severance costs in 2025.","Reiterates FY2025 revenue guidance $155-170M and non-GAAP gross margin 35-40%; targets positive cash flow by end of 2027.","Cash and investments $343.1M at Q1 end; expects higher ending balance after cost cuts."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":37153000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171037,"accession_number":"0001299130-25-000072","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PacBio appoints Jim Gibson as CFO, effective March 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jim Gibson appointed CFO effective March 31, 2025; Christian Henry ceases as interim CFO.","Gibson previously CFO at Sequoia and Willow Innovations; held exec roles at GoDaddy, Tesla, Apple, Netflix.","Compensation: $500k base salary, 55% target bonus, 2M stock options, 1M RSUs with standard vesting.","Severance provides 12 months salary and COBRA; change-in-control triggers full equity acceleration.","PacBio targets positive cash flows by end of 2027, per press release announcing Gibson's hiring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171036,"accession_number":"0001299130-25-000053","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Pacific Biosciences extends Menlo Park lease to 2034, gets $11.6M rent abatement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease term extended to April 30, 2034 from Oct 31, 2027; 180,231 sq ft.","Base rent ranges from $5.70 to $6.81/sq ft/month; monthly rent ~$1.03M to ~$1.23M.","Seventeen months rent abatement totaling $11.64M; tenant improvement allowance $7.21M.","Option to extend through April 2044 at fair market rent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171035,"accession_number":"0001299130-25-000033","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PacBio Q4 rev $39.2M (-33% YoY), $90M impairment, non-GAAP loss $55.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $39.2M vs $58.4M prior year; instrument revenue fell to $15.3M from $35.1M.","GAAP net income of $3.6M includes $154.4M gain on debt restructuring; non-GAAP net loss $55.3M ($0.20 loss per share).","Preliminary non-cash impairment charges of ~$90.1M for goodwill and IPR&D due to macroeconomic headwinds.","Cash $389.9M, down from $631.4M; convertible note exchange reduced principal by $259M.","Launched Vega benchtop platform and SPRQ chemistry enabling sub-$500 genome, with 23 Revio and 7 Vega systems shipped."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":154014000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171032,"accession_number":"0001299130-25-000027","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K/A","filed_at":"2025-02-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pacific Biosciences appoints Smith to Science & Technology Committee, Mohr as Audit chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher M. Smith appointed to Science and Technology Committee effective February 6, 2024.","Marshall Mohr named chairman of Audit Committee, replacing Randy Livingston (remains member).","Both appointments made upon recommendation of the Corporate Governance and Nominating Committee.","Smith will receive additional cash compensation per non-employee director policy detailed in prior proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171034,"accession_number":"0001299130-25-000015","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PacBio appoints NeoGenomics CEO Chris Smith to board; David Meline resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chris Smith, CEO of NeoGenomics (NEO), appointed to PacBio Board effective Jan 30, 2025.","David Meline resigned from Board effective Jan 30, 2025; no disagreement cited.","Smith brings diagnostics and genomics expertise as PacBio expands into clinical genomics.","Smith previously led Ortho Clinical Diagnostics (sold to Quidel) and Cochlear Limited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171033,"accession_number":"0001299130-25-000011","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"PacBio reports preliminary Q4 revenue $39.2M, down 33% YoY; Vega system shipped ahead of schedule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q4 revenue $39.2M vs $58.4M prior year (-33%); full year $154M vs $200M (-23%).","Instrument revenue $15.3M (23 Revio, 7 Vega systems); consumables revenue $18.8M flat YoY.","Launched Vega benchtop system ahead of schedule and SPRQ chemistry enabling sub-$500 HiFi genome.","Strengthened balance sheet: exchanged $459M of 2028 notes for $200M notes due 2029, 20.5M shares, and $50M cash.","Preliminary cash and investments $390M as of Dec 31, 2024; final results subject to audit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188008,"accession_number":"0001299130-24-000200","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pacific Biosciences amends CEO/COO severance: lump sum 12-18 months salary, extended change-of-control window","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Christian Henry receives lump sum cash severance equal to 18 months of base salary.","COO Mark Van Oene receives lump sum cash severance equal to 12 months of base salary.","Change-of-control period expanded to include 3 months prior to a change in control.","Company also amended and restated the form change-in-control agreement for all executive officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188002,"accession_number":"0001299130-24-000198","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K/A","filed_at":"2024-12-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Pacific Biosciences discloses CCO Jeff Eidel's separation terms: $485K severance, 12-month COBRA","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeff Eidel's employment as CCO ended Nov 15, 2024; separation agreement signed Dec 6, effective Dec 13.","Eidel receives lump sum of $485,000 (12 months base salary) and up to 12 months COBRA premium payments.","Vested stock options must be exercised within 3 months of separation or forfeited; unvested RSUs/PSUs cancelled.","Eidel agrees to release all claims, maintain confidentiality, and refrain from disparagement.","Company will instruct executive officers and board to refrain from disparaging Eidel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188007,"accession_number":"0001299130-24-000192","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pacific Biosciences CFO Susan G. Kim resigns; CEO Christian Henry appointed interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Susan G. Kim resigned as CFO and principal financial officer effective December 6, 2024.","President and CEO Christian Henry appointed interim CFO effective December 6, 2024, with no change in compensation.","Henry continues as CEO; the Board has not announced a permanent CFO search."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188006,"accession_number":"0001299130-24-000189","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Pacific Biosciences exchanges $459M 2028 notes for $200M new notes, shares, and $50M cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged $459M of 1.50% 2028 notes for $200M new 1.50% notes due 2029, 20,451,570 shares, and $50M cash.","All $459M of the 2028 notes have been cancelled; no cash proceeds received by the company.","New notes mature August 15, 2029, convertible at ~$4.89/share, callable after Aug 2027 if stock >150% of conversion.","Side letter with SBN restricts new debt and liens; right of first refusal if going-concern doubt triggers up to $200M.","Covenants include no indebtedness maturing before 2029 (except permitted) and no guarantees without equal treatment of notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188005,"accession_number":"0001299130-24-000185","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pacific Biosciences CCO Jeff Eidel to depart Nov 15 amid commercial restructuring","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeff Eidel notified of separation as Chief Commercial Officer on November 11, 2024.","Separation effective November 15, 2024, due to internal restructuring of commercial organization.","Eidel's responsibilities reallocated to CEO Christian Henry; no compensation increase for Henry."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188004,"accession_number":"0001104659-24-115295","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"PacBio Q3 revenue falls 28% to $40M; CFO resigns; notes exchange with SoftBank","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $40.0M (-28% YoY); instrument revenue $16.8M (down from $34.7M); 22 Revio systems shipped.","Net loss $60.7M ($0.22/sh) vs $66.9M ($0.26) prior year; non-GAAP net loss $46.0M ($0.17).","CFO Susan Kim resigns effective Dec 6; no severance; search for replacement underway.","Announced $459M convertible note exchange (1.50% due 2028) with SoftBank, expected close Nov 21.","Launched SPRQ chemistry increasing Revio throughput 33%; unveiled Vega benchtop sequencer at $169K."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":114790000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188003,"accession_number":"0001104659-24-115291","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["1.01","2.03","8.01","3.02","9.01"],"status":"ready","headline":"PacBio exchanges $459M 2028 notes for $200M 2029 notes, 20.5M shares, $50M cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged $459M of 1.5% 2028 notes for $200M new 1.5% 2029 notes, 20.45M shares, and $50M cash.","New notes mature Aug 2029, convertible at ~$4.89/share; interest paid semi-annually.","All 2028 notes to be cancelled; none remain after close on/about Nov 21, 2024.","Transaction extends debt maturity to 2029 and reduces principal by $259M but adds dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204511,"accession_number":"0001299130-24-000164","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PacBio Q2 revenue down 24% to $36M; GAAP net loss $173M includes $93M goodwill impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $36.0M vs $47.6M YoY; instrument revenue fell to $14.7M from $29.9M.","GAAP net loss $173.3M (-$0.64/sh); non-GAAP net loss $55.2M (-$0.20/sh).","Goodwill impairment charge of $93.2M; restructuring expenses of $18.0M included.","Cash $509.8M, down from $631.4M at Dec 31, 2023.","CEO expects revenue acceleration in H2; targeting >$75M annual expense reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":74823000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204510,"accession_number":"0001299130-24-000165","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K/A","filed_at":"2024-08-07T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Pacific Biosciences estimates $27M in charges for expense reduction plan; San Diego office closure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total charges estimated at $27M in fiscal 2024, including $10M compensation, $12M lease costs, $4M inventory.","Cash expenses of ~$21M: $10M severance and benefits, $11M San Diego office closure and lease costs.","Substantially all charges expected in Q2 and Q3 2024; company had previously disclosed plan on April 16, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221315,"accession_number":"0001299130-24-000146","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"PACB shareholders approve 20M share increase, board declassification, officer exculpation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2020 Equity Incentive Plan, adding 20,000,000 shares for issuance.","Board declassification over three-year period beginning at 2025 annual meeting approved.","Amendment limiting officer liability as permitted by Delaware law approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221314,"accession_number":"0001299130-24-000109","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PacBio Q1 revenue flat at $38.8M; net loss $78.2M; cuts 195 jobs to reduce expenses","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $38.8M (flat YoY); instrument revenue down 8% to $19.0M; consumables up 14% to $16.0M.","GAAP net loss $78.2M ($0.29 loss per share) vs $88.0M loss ($0.36) in Q1 2023; non-GAAP loss $71.4M ($0.26).","Cash and investments $561.9M at March 31, 2024, down from $631.4M at Dec 31, 2023.","Announced ~195 headcount reduction to cut non-GAAP annualized expense run rate by >$75M by end of 2024.","Management cites increasing customer delays in instrument purchases; targeting positive cash flows by end of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":38810000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221313,"accession_number":"0001104659-24-047511","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["2.02","2.05","8.01","9.01"],"status":"ready","headline":"PacBio reports preliminary Q1 rev $38.8M (flat YoY), slashes FY2024 guidance to $170-200M, cuts costs $50-75M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 2024 revenue $38.8M, roughly flat vs $38.9M in prior-year period.","Revio shipments 28 systems in Q1; installed base reached 201 as of March 31, 2024.","FY2024 revenue guidance reduced to $170-200M; long-term $500M 2026 goal unlikely.","Plan to reduce annualized non-GAAP operating expense run rate by $50M-$75M by end of 2024.","Cash, cash equivalents & investments expected to be $435-450M by year-end, down from $562M at Q1 end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":38810000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240868,"accession_number":"0001299130-24-000014","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PacBio Q4 rev $58.4M (+113% YoY) but GAAP gross margin drops to 16%; FY rev $200.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $58.4M (+113% YoY); instrument revenue $35.1M vs $6.1M YoY.","GAAP gross margin 16% (vs 19% YoY); $9.3M inventory reserve charges from faster Revio ramp.","Net loss $82.0M ($0.31/share) vs $84.4M ($0.37) PY; non-GAAP loss $72.5M.","Shipped 44 Revio systems; installed base 173; consumables revenue $18.9M (+13% YoY).","FY2023 rev $200.5M (+56% YoY); net loss $306.7M vs $314.2M; cash $631.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":200521000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240867,"accession_number":"0001299130-24-000005","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"PacBio reports record preliminary Q4 revenue $58.4M, up 113% YoY; Revio installed base 173","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary full year 2023 revenue $200.5M, up 56% YoY; Q4 revenue $58.4M (+113% YoY).","Shipped 44 Revio systems in Q4, total installed base 173; annualized pull-through ~$385K per system.","Preliminary Q4 consumables revenue $18.9M (67% from Revio); instrument revenue $35.1M.","Cash, equivalents, and investments $631M as of Dec 31, 2023.","Reaffirms 40-50% annual revenue growth target through 2026, aiming for >$500M in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":200521000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258369,"accession_number":"0001299130-23-000142","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director David Botstein resigns from Pacific Biosciences board effective Dec 7, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Botstein notified the board of his resignation, effective December 7, 2023.","No disagreement existed between Botstein and the company regarding operations, policies, or practices.","Botstein's departure reduces board size; no replacement announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258368,"accession_number":"0001299130-23-000135","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PacBio Q3 revenue $55.7M (+72% YoY); net loss narrows to $66.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $55.7M, up 72% YoY; instrument revenue $34.7M from 52 Revio systems (prior year $11.4M).","Consumables revenue $16.9M (record; +5% YoY) with Revio consumables surpassing Sequel II/IIe.","GAAP net loss $66.9M ($0.26/shr) vs $77.0M ($0.34/shr) prior year; Non-GAAP net loss $67.9M ($0.27).","Gross margin 32% vs 42% prior year; non-GAAP gross margin also 32%.","Cash and investments $767.8M; launched leasing program, first Onso shipments, and new WGS variant pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":142164000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258366,"accession_number":"0001299130-23-000130","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K/A","filed_at":"2023-10-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pacific Biosciences appoints David Meline to Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board appointed David Meline to Audit Committee, effective October 24, 2023.","Meline previously appointed as Class II director on October 13, 2023.","Amendment No. 1 to Form 8-K adds committee assignment details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258367,"accession_number":"0001299130-23-000122","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2023-10-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PacBio appoints former Moderna CFO David Meline to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Meline appointed as Class II director effective October 13, 2023, term expiring at 2024 annual meeting.","Meline most recently served as CFO of Moderna; previously CFO of Amgen and 3M, with 20+ years at GM.","He also serves on boards of ABB Ltd. and will join HP Inc. board on November 1, 2023.","Meline will participate in standard non-employee director compensation policy and indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275671,"accession_number":"0001104659-23-103181","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K/A","filed_at":"2023-09-22T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Pacific Biosciences to issue ~8.9M shares and $101M cash for Omniome milestone","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["On Sep 20, 2023, PacBio achieved a commercial milestone under the Omniome merger agreement.","Former Omniome holders will receive approx. $101M cash + 8.9M shares (valued at ~$100M based on 20-day VWAP).","Shares issuance expected on or about October 4, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275672,"accession_number":"0001299130-23-000093","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","3.02","7.01","9.01"],"status":"ready","headline":"PacBio Q2 revenue $47.6M (+34% YoY); acquires Apton for up to $110M; Onso shipments start","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $47.6M (+34% YoY); Revio drove record revenue with 45 systems shipped.","Net loss $69.8M ($0.28 GAAP EPS); non-GAAP net loss $65.6M ($0.26).","Acquired Apton Biosystems for ~$85M in stock plus up to $25M contingent milestone, valued up to ~$110M.","Commercial shipments of Onso short-read sequencer commenced; first customer shipment today.","Cash and investments $829.9M at June 30; issued $441M 1.375% convertible notes due 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":86473000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293217,"accession_number":"0001104659-23-077161","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Pacific Biosciences exchanges $441M of 2028 notes for new 1.375% 2030 convertible notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $441M principal of 1.375% Convertible Senior Notes due 2030 in exchange for $441M of 1.50% 2028 Notes.","No cash proceeds; accrued interest paid on exchanged notes; $459M of 2028 Notes remain outstanding.","New notes mature Dec 15, 2030, convertible at ~46.5116 shares/$1,000 (initial conversion price ~$21.50/share).","Notes redeemable after June 20, 2028 if stock price exceeds 150% of conversion price for 20 of 30 consecutive trading days.","Transaction privately negotiated with Chimera Investment LLC under Section 4(a)(2) exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293216,"accession_number":"0001104659-23-074397","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["1.01","2.03","8.01","3.02","9.01"],"status":"ready","headline":"PacBio exchanges $441M of 1.50% 2028 notes for $441M of 1.375% 2030 notes with Chimera","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged $441M of 1.50% 2028 Convertible Notes for $441M of new 1.375% 2030 Convertible Notes with Chimera Investment LLC.","New notes convertible at ~$21.50/share (46.5116 shares per $1,000 principal); interest payable semi-annually.","After exchange, $459M of original 2028 Notes remain outstanding with unchanged terms.","Lock-up on Chimera for 3 months; beneficial ownership limited to 4.99% (max 9.99%). Expected close June 30, 2023.","CEO says exchange extends debt duration and strengthens cash position; company targeting positive cash flows in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293215,"accession_number":"0001299130-23-000070","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2023-05-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pacific Biosciences stockholders reject classified board retention in advisory vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Class I directors Henry, Milligan, Shapiro with >178M votes each for three-year terms.","Ratified Ernst & Young as independent auditor for FY2023 (218.3M for, 622.6K against).","Advisory say-on-pay approved with 178.1M votes for, 14.6M against.","Say-on-pay frequency: 1 year preferred (134.2M votes) over 3 years (58.3M).","Advisory vote on retaining classified board: 136.3M against, 32.3M for, with 24.3M abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293214,"accession_number":"0001299130-23-000047","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PacBio reports record Q1 revenue $38.9M (+17% YoY) but net loss widens to $88.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $38.9M (+17% YoY); net loss $88.0M ($0.36 loss per share) vs $81.5M loss prior year.","Shipped 38 sequencing systems (32 Revio, 6 Sequel IIe); Revio launch exceeding expectations with record backlog.","GAAP gross margin fell to 25% from 43% YoY due partly to $3.5M charge for excess Sequel II/IIe consumables.","Cash and investments $874.9M at March 31 vs $772.3M at Dec 31, 2022.","Received first orders for Onso short-read system; introduced new workflows and DNA extraction kits."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":38900000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313856,"accession_number":"0001299130-23-000022","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2023-02-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PacBio Q4 revenue down 24% YoY to $27.4M; net loss $84.4M; record Revio orders","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 GAAP net loss $84.4M ($0.37 EPS) vs $69.3M loss ($0.31 EPS) a year ago.","Revenue $27.4M, down 24% YoY; instrument revenue fell 62% to $6.1M.","Record orders for 96 instruments, including 76 Revio systems from 43 customers.","Gross margin fell to 19% from 47%, impacted by $7.1M loss on purchase commitments.","Raised ~$201M in January 2023 public offering; Revio commercial shipments begin March 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":128304000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313855,"accession_number":"0001104659-23-007513","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2023-01-27T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"PacBio prices 17.5M-share offering at $10/shr; expected net proceeds ~$189.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 17.5M shares plus full exercise of underwriter option for 2.625M additional shares at $10.00 per share.","Gross proceeds ~$175M before option; net proceeds after discounts/expenses expected ~$189.2M.","Net proceeds to fund R&D, commercial infrastructure, working capital, and potential acquisitions.","Underwriters include Goldman Sachs, Morgan Stanley, Cowen, and Allen & Company; offering closed January 27, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313854,"accession_number":"0001104659-23-006228","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2023-01-24T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"PacBio announces $150M public stock offering to fund R&D, commercial expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposed offering of $150M common stock; underwriters have 30-day option for additional $22.5M.","Goldman Sachs, Morgan Stanley, Cowen, and Allen & Co. acting as joint book-running managers.","Net proceeds for R&D, commercial infrastructure, working capital, and potential acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313853,"accession_number":"0001299130-23-000010","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"PacBio reports Q4 preliminary revenue $27.3M (-24% YoY); received orders for 76 Revio systems","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 preliminary revenue $27.3M, down 24% from $36.0M in Q4 2021.","Full-year 2022 preliminary revenue $128.2M, down 2% from 2021.","Received orders for 76 Revio systems in Q4 2022, record product announcement.","Cash, cash equivalents, and investments ~$772.3M as of Dec 31, 2022.","Onso beta feedback positive; orders expected Q1 2023, shipments by end of Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":128304000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":332309,"accession_number":"0001299130-22-000128","cik":1299130,"company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","ticker":"PACB","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","5.03","9.01"],"status":"ready","headline":"PacBio Q3 2022 revenue down 7% YoY to $32.3M; net loss $77M; withdraws guidance; launches Revio and Onso systems","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $32.3M (down 7% YoY); instrument revenue $11.4M (down 28%); consumables revenue $16.1M (up 10%).","GAAP net loss $77.0M ($0.34 EPS) vs net income $16.5M ($0.08 EPS) in Q3 2021; non-GAAP net loss $72.5M ($0.32 EPS).","Cash and investments $834.3M, down from $1,044.4M at Dec 2021; withdrawn all prior financial guidance.","Launched Revio long-read system (up to 1,300 human genomes/year, <$1k/genome) with shipments starting Q1 2023.","Introduced Onso short-read system with 10x accuracy improvement; shipments expected H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":100951000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":438818046.7137984,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-07T23:59:59+00:00|332309"}